·

eGenesis Stock: Enabling Pig-to-Human Organ Transplants

This page contains links to our partners. We may be compensated when a link is clicked. Read the disclosures to learn more.

eGenesis logo. Explore opportunities to invest in eGenesis stock before the eGenesis IPO. Follow along as the startup attempts to commercialize its technology and grows into a public company.

Explore news and facts about the pig-to-human organ transplant startup and the potential to own eGenesis stock before an IPO. 


Notable eGenesis News

09/04/2024: eGenesis Raises $191 Million Series D
03/21/2024: eGenesis Announces World’s First Pig/Human Kidney Transplant
03/02/2021: eGenesis Announces $125 Million Series C
Older news…

About eGenesis

eGenesis is a biotechnology startup based in Cambridge, Massachusetts. Its scientists are developing techniques to use gene editing to address the widespread shortage of transplant organs.

The company was founded in 2015 by Dr. Luhan Yang and accomplished geneticist George Church. The founders worked together at Harvard Medical School.

The duo and their team demonstrated they could eliminate latent pig viruses hidden inside the pig’s genome using CRISPR gene editing. This was the first step on a long path to commercialization.  

Their mission is to make xenotransplantation — transplanting animal organs into humans — possible by genetically modifying porcine organs to be safe and compatible for human use.

The company achieved a significant milestone in 2017 by creating the first pigs free of retroviruses, a crucial step toward safe xenotransplantation. The company’s successes led to multiple venture capital rounds to bring their processes to market. 

eGenesis has advanced to conducting preclinical trials. It successfully completed its first pig-to-human kidney transplant in March 2024. 

Future plans include scaling up capabilities and securing regulatory approvals for more human clinical trials. 

Here’s a video introducing eGenesis:

Meet eGenesis - A Leaps Portfolio Company

Ownership

eGenesis is a venture-backed startup. Its equity ownership participants include the founders, employees, and several venture capital firms. 

Prominent venture capital investors include Lux Capital, ARCH Ventures, Khosla Ventures, Farallon Capital, Alta Partners, Fresenius Medical Care Ventures, Leaps by Bayer, DaVita, Eisai Innovation, NATCO Pharmaceuticals, Parkwood Corporation, Polaris Partners, HBM Healthcare, Invus, Samsara BioCapital, LifeSci Venture Partners, Irving Investors, Catalio Capital, SymBiosis, Altium Capital, Monashee, Osage University Partners, and Wellington Partners.

Funding Rounds

Round Date Est. Valuation Raise Amount Price
Series D 9/4/2024 NA $191.00M NA
Series C 2/28/2021 $350.00M $125.00M $1.95
Series B 10/31/2019 $175.00M $100.00M $1.81
Series A 3/12/2017 $54.87M $38.00M $1.80
Source: Caplight
WordPress Data Table Plugin

Valuation

The latest confirmed eGenesis valuation is $350 million based on the Series C funding round completed in February 2021. 

However, the September 2024 Series D funding round changed the valuation. According to multiple sources, the updated private valuation is around $330 million. 

IPO Potential

The eGenesis IPO date has yet to be determined and is likely many years down the line, contingent upon its ability to refine the science and gain regulatory approval. 

However, biotech companies sometimes go public early to raise additional funds in anticipation of regulatory approval. In eGenesis’s case, it has demonstrated the capability to raise significant cash from private investors, possibly delaying the need to IPO. 

We’ll get clues about a potential eGenesis IPO date if the company hires a CFO with IPO experience or says it is talking to investment banks. Reporters often receive leaks and clues about startup intentions to go public to attract public interest.

An S-1 filing (confidentially or public) is the most accurate sign that an IPO may be forthcoming. 

How to Invest in eGenesis Stock

Share scarcity makes startups below a $1 billion valuation challenging to invest in. Most early investors and employees are invested in the long-term outcome, becoming a viable business that is revolutionizing a healthcare need.

Because of the SEC accreditation requirement, most individuals cannot own eGenesis stock directly via pre-IPO investing platforms. Accredited investors can explore private ownership, but I have yet to see share availability on any major platform.

Non-accredited investors can evaluate venture capital funds to find access to pre-IPO startups. But eGenesis is still in an early stage, challenging fund managers to acquire equity. 

Here are some potential options to own eGenesis stock before, during, and after the IPO.

1. Access eGenesis stock pre-IPO

Pre-IPO investment platforms may offer eGenesis stock for purchase as employees or early investors seek to sell some of their shares before the eGenesis IPO.

Accredited investors may access shares, provided they are registered on the platform and receive notifications about their availability.

Monitor pre-IPO investing platforms such as Hiive, Forge Global, EquityZen, and Linqto for share availability.

Investment minimums on these platforms range from $2,500 to $50,000, and deal-specific minimum investment amounts will vary.

Venture capital funds are a new asset class that emerged in 2022 that allows non-accredited investors to own pre-IPO startups. 

The Fundrise Innovation Fund (review) is the most promising for patient, long-term investors. It holds multiple AI and technology startups. U.S.-based investors can make their first investment for $10. However, eGenesis is not currently a fund holding, and biotech is not a foundational investment thesis. 

Investors can own AI private stocks like OpenAI, Anthropic, and Databricks instead of eGenesis.

Check out our top pre-IPO investing platforms for the latest share availability. 

Please note: This is a testimonial in partnership with Fundrise. We earn a commission from partner links on AccessIPOs.com. All opinions are my own.

2. Participate in the eGenesis IPO through a broker

When a company eventually goes public, investors can buy the stock during the IPO at the IPO price. I don’t expect eGenesis to go public anytime soon, but it’s on our radar. 

Often, only Wall Street’s top customers can invest in IPOs. But now, ordinary investors can access IPOs through participating discount brokers. 

Some online brokers (like the ones listed below) allow investors to invest in IPOs for free, even if they have limited funds in their accounts.

TradeStation has a more established track record of accessing more than 400 IPOs and secondary offerings via its partnership with Click Markets (formerly ClickIPO).

Robinhood has the advantage of Silicon Valley networks and a history of getting allocations for high-profile IPOs.

Check out this list of best brokers for IPO investing to learn more about IPO access for retail investors.

3. Buy the stock after the eGenesis IPO

Waiting for the IPO provides access to established financials after the initial trading quarter, whereas pre-IPO investing has reduced transparency.

High-demand companies may be overvalued at the time of their public offering, selling shares near their peak. Share may be at risk of significant losses upon market corrections.

Despite high initial valuations, stock prices sometimes decline after the first and second-quarter earnings reports post-IPO.

While stock price declines can make good entry points for long-term buy-and-hold investors, watch out for lockup expirations and earnings discrepancies as they may impact price movements. 

Patience is essential. The most disruptive companies may perform better over time.

Frequently Asked Questions (FAQs)

Is eGenesis publicly traded?

No. eGenesis is not publicly traded. It is a private company. 

What is the eGenesis stock price?

A public eGenesis stock price does not exist.

However, eGenesis completed its February Series C funding round at a stock price of $1.95 per share. 

What is the eGenesis stock symbol?

There is no eGenesis stock symbol because the company is private. The company may reserve a stock symbol while planning to file for an IPO. The reserved symbol will be revealed when the S-1 filing is released to the public.

The symbol “EGEN” is available in the U.S. and would be the most likely eGenesis ticker should the company go public.

Though private information regarding forthcoming IPOs typically leaks to the press, startup stock symbols are usually not confirmed until the filing. 

Where is the eGenesis IPO S-1 Filing?

eGenesis has not filed for an IPO, nor does it have plans to. So, an S-1 filing is a long way from becoming available. 

The document will become available if the company submits filings to the SEC and the regulatory commission approves and releases it to the public. 

We’ll post a copy of the S-1 filing on this page when it becomes available.  

You can monitor the most recent S-1 IPO filings on this website.

News Archive

11/07/2019: eGenesis Announces $100 Million Series B
03/16/2017: CRISPR May Speed Pig-to-Human Transplants
10/15/2015: Editing of Pig DNA May Lead to More Organs for People

Conclusion

Product users and potential investors become excited when they discover companies capitalizing on macroeconomic trends like gene editing techniques like CRISPR being deployed by companies like Mammoth Biosciences, Colossal

eGenesis may be uniquely positioned to profit from creating organ transplants compatible with humans. Once perfected, the techniques could be used to scale pig farming and organ harvesting for human use, a potential solution for the donor organ shortage.  

But buying private stock early on can be challenging for ordinary investors despite wanting to own the company, especially when a company’s valuation is below $1 billion. 

Multiple pre-IPO platforms now provide opportunities for ordinary investors. However, venture capital investment is still primarily reserved for the ultra-wealthy, meaning investors need significant wealth to invest in seed and early funding rounds.

The risks of owning pre-IPO stocks may outweigh the potential gains, so proceed cautiously. 

When pursuing IPO shares and early equity in eGenesis stock, have reasonable expectations. Shares are likely to be unavailable or restricted for ordinary investors looking to own the stock. 

Invest in pre-IPO and IPO companies with caution. Good luck if the eGenesis stock is on your watch list.

* Disclosure: The web page contains affiliate links from our partners. If a reader opens an account or buys a service from a link in this article, we may be compensated at no additional cost. Opening an account with a broker that provides access to IPOs does not guarantee the customer allocations of specific IPOs. The author is long the Fundrise Innovation Fund and HOOD.

Risk Statement: Investing in IPOs and pre-IPO startups involves significant risk. Do not invest in companies based solely on what is included in this article. Only invest in IPOs and pre-IPO companies with money you can afford to lose.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.